Esperion Therapeutics, Inc. ("Esperion") has announced a proposed public offering of its common stock. The company plans to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of its common stock offered in the public offering. Piper Sandler & Co. and Cantor Fitzgerald & Co. are acting as joint book-running managers for the proposed offering.
Esperion's shares of common stock are being offered pursuant to an effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (SEC) on April 18, 2025, and declared effective by the SEC on April 29, 2025 (file no. 333-286631).
The company's press release also shares details about Esperion Therapeutics, highlighting its focus on developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Esperion developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated LDL-C.
Esperion's next generation program is focused on developing ATP citrate lyase inhibitors (ACLYI), and the company continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations, and advancement of its pre-clinical pipeline. Following these announcements, the company's shares moved -16.83%, and are now trading at a price of $2.57. If you want to know more, read the company's complete 8-K report here.
